| Literature DB >> 31921840 |
Elena Stocco1,2,3, Silvia Barbon1,2,3, Monica Piccione4, Elisa Belluzzi5,6, Lucia Petrelli1, Assunta Pozzuoli5,6, Roberta Ramonda7, Marco Rossato8, Marta Favero7, Pietro Ruggieri6, Andrea Porzionato1,2, Rosa Di Liddo3,4, Raffaele De Caro1,2, Veronica Macchi1,2.
Abstract
Recently, infrapatellar fat pad (IFP) has been considered as a source of stem cells for cartilage regeneration in osteoarthritis (OA) due to their ability for differentiation into chondrocytes. However, stressful conditions, like that related to OA, may induce a pathogenic reprograming. The aim of this study was to characterize the structural and functional properties of a new population of stem cells isolated from osteoarthritic infrapatellar fat pad (OA-IFP). Nine OA patients undergoing total knee arthroplasty (TKA) were enrolled in this study [median age = 74 years, interquartile range (IQR) = 78.25-67.7; median body mass index = 29.4 Kg/m2, IQR = 31.7-27.4]. OA-IFP stem cells were isolated and characterized for morphology, stemness, metabolic profile and multi-differentiative potential by transmission electron microscopy, flow cytometric analysis, gene expression study and cytochemistry. OA-IFP stem cells displayed a spindle-like morphology, self-renewal potential and responsiveness (CD44, CD105, VEGFR2, FGFR2, IL1R, and IL6R) to microenvironmental stimuli. Characterized by high grade of stemness (STAT3, NOTCH1, c-Myc, OCT-4, KLF4, and NANOG), the cells showed peculiar immunophenotypic properties (CD73+/CD39+/CD90+/CD105+/CD44-/+/CD45-). The expression of HLA-DR, CD34, Fas and FasL was indicative of a possible phenotypic reprograming induced by inflammation. Moreover, the response to mechanical stimuli together with high expression level of COL1A1 gene, suggested their possible protective response against in vivo mechanical overloading. Conversely, the low expression of CD38/NADase was indicative of their inability to counteract NAD+-mediated OA inflammation. Based on the ultrastructural, immunophenotypic and functional characterization, OA-IFP stem cells were hypothesized to be primed by the pathological environment and to exert incomplete protective activity from OA inflammation.Entities:
Keywords: inflammation; infrapatellar fat pad; osteoarthritis; reprograming; stem cells
Year: 2019 PMID: 31921840 PMCID: PMC6914674 DOI: 10.3389/fcell.2019.00323
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Patient’s demographic data.
| 1 | F | 68 | 29.4 | 3 | H |
| 2 | F | 67 | 27.7 | 3 | H |
| 3 | F | 74 | 30.1 | 3 | H, D |
| 4 | M | 64 | 27.4 | 3 | H, D2 |
| 5 | M | 73 | 36.3 | 4 | H, D2 |
| 6 | F | 79 | 24.5 | 3 | H, D, D2 |
| 7 | F | 76 | 27.3 | 3 | H, D |
| 8 | M | 79 | 32.3 | 3 | H, D |
| 9 | F | 78 | 31.6 | 3 | H, D |
Oligonucleotides used for RT qPCR analysis.
| F: ATGGACAGGACTGAACGTCTTGCT | NM_000194.2 | 79 pb | ||
| R: TTGAGCACACAGAGGGCTACAATG | ||||
| F: CTCAATGGATCCCGCAGTAAA | D_84276.1 | 145 pb | ||
| R: CCTGGCATAAGTCTCTGGAATC | ||||
| F: TCTCCCGATCCCAGTATCTATG | NM_004343.3 | 109 pb | ||
| R: CATCGTTGGTGATGAGGAAGT | ||||
| F: ACATGGAGAACAAGCTGTTTGCGG | NM_198253.2 | 66 pb | ||
| R: TGAGGTGAGGTGTCACCAACAAGA | ||||
| F: TGGAGGAATTACCTGGCATTGACCT | NM_174900.3 | 105 pb | ||
| R: AGCGATTGCGCTCAGACTGTCATA | ||||
| F: ACAACATGATGGAGACGGAGCTGA | NM_003106.3 | 191 pb | ||
| R: TGGTAGTGCTGGGACATGTGAAGT | ||||
| F: ATGGAAGAATCCAACAACGGCAGC | NM_213662.1 | 175 pb | ||
| R: AGGTCAATCTTGAGGCCTTGGTGA | ||||
| F: TCAGGGTGTGCACTGTGAGATCAA | NM_017617.3 | 112 pb | ||
| R: AGGTGCCGTTGTTAAAGCACTTGG | ||||
| F: CTCCACACATCAGCACAACTA | D10493.1 | 79 pb | ||
| R: TGTCCAACTTGACCCTCTTG | ||||
| F: TATGCAAAGCAGAAACCCTCGTGC | NM_002701.4 | 102 pb | ||
| R: TTCGGGCACTGCAGGAACAAATTC | ||||
| F: TGAACTGACCAGGCACTACCGTAA | NM_004235.4 | 106 pb | ||
| R: TCTTCATGTGTAAGGCGAGGTGGT | ||||
| F: CCCAAAGGCAAACAACCCACTTCT | NM_024865.2 | 106 pb | ||
| R: AGCTGGGTGGAAGAGAACACAGTT | ||||
| F: CGATGGCTGCACGAGCTACAC | NM_000088.3 | 179 pb | ||
| R: TGTCCTCATCCCTCTCATACA | ||||
| F: CGGGCAGAGGGCAATAGCAGGTT | NM_001844.4 | 127 pb | ||
| R: CAATGATGGGGAGGCGTGAG | ||||
| F: AATCAGGCTCTCGAAGCTCATAAAA | NM_001853.3 | 99 pb | ||
| R: CCTGCCACACCCCCGCTCCTTCAT | ||||
| F: GAACTCCCAGCACGCAGAATCC | NM_000493.3 | 144 pb | ||
| R: GTGTTGGGTAGTGGGCCTTTTATG | ||||
| F: TACATCGGGCCTTGCAAATA | J03040.1 | 121 pb | ||
| R: CAGGTTGGGATGGAGGGAGTTTAC | ||||
| F: GCAGAAGGATCGGATGGATAAG | BC008799.2 | 90 pb | ||
| R: GCTTCGACAGGTACTGTCTTC | ||||
| F: GTGCTCCTGGTTCTGTTCTT | NM_006516.3 | 126 pb | ||
| R: CTCGGGTGTCTTGTCACTTT | ||||
| F: GCCCTACGTCTTCCTTCTATTT | NM_001042.2 | 150 pb | ||
| R: GGTTTCACCTCCTGCTCTAAA |
Antibodies used for flow cytometry analysis.
| PE anti-human CD34 (BI-3C5) | sc-19621 | Santa Cruz Biotechnology, Inc |
| Mouse anti-human CD39 | sc-65262 | Santa Cruz Biotechnology, Inc |
| PE anti-human CD44 (H-CAM F-4) | sc-9960 | Santa Cruz Biotechnology, Inc |
| PE anti-human CD45 (2D1) | sc-1187 | Santa Cruz Biotechnology, Inc |
| PE anti-human CD73 | 344004 | BioLegend, Inc |
| FITC anti-human CD90 (aTHy-1A1) | sc-53456 | Santa Cruz Biotechnology, Inc |
| PE anti-human CD117 (c-Kit Ab81) | sc-13508 | Santa Cruz Biotechnology, Inc |
| PE anti-human CD105 (Endoglin P3D1) | sc-18838 | Santa Cruz Biotechnology, Inc |
| PE mouse anti-human HLA-DR (L243) | sc-18875 | Santa Cruz Biotechnology, Inc |
| A350 anti-human IL1R1 | bs-2594R | Bioss |
| Rabbit anti-human IL6R | AB-83485 | Immunological Sciences |
| APC anti-human FGFR2 | FAB 684A | R&D Systems, Inc |
| PE anti-human PDGFRβ | 558417 | BD Biosciences |
| FITC anti-human VEGFR2/KDR | FAB 357F | R&D Systems, Inc |
| PE anti-human CD95 (Fas) | 555674 | BD Biosciences |
| APC anti-human CD178 (FasL) | 564262 | BD Biosciences |
| AF488 goat anti-mouse | A32723 | Invitrogen |
| AF488 goat anti-rabbit | A32731 | Invitrogen |
| PE isotype control | sc-2855 | Santa Cruz Biotechnology, Inc |
| PE isotype control | 400114 | BioLegend, Inc |
| PE isotype control | 554680 | BD Biosciences |
| FITC isotype control | sc-2855 | Santa Cruz Biotechnology, Inc |
| FITC isotype control | IC002F | R&D Systems, Inc |
| APC isotype control | IC002A | R&D Systems, Inc |
| APC isotype control | 555751 | BD Biosciences |
| A350 isotype control | bs-0295P | Bioss |
FIGURE 1Osteoarthritic infrapatellar fat pad (OA-IFP) and derived cells. (A) Magnetic resonance imaging of the knee in sagittal section, showing the infrapatellar fat pad (IFP – white arrow) before total knee arthroplasty(TKA). (B) Gross appearance of the IFP after surgical excision and before tissue enzymatic digestion for cells isolation. (C) Representative optical microscope image of the IFP stem cells at P0 in culture. P, passage. Scale bar, 100 μm.
FIGURE 2Proliferative potential and metabolic activity. (A) Optical microscope images of OA-IFP cells in proliferative medium at P8 and P20. P: passage. Scale bars, 100 μm. (B) Population Doubling Level (PDL) calculated throughout 12 generations; cells performed 11.9 ± 8.3 population doublings. (C) Vitality/necrosis/apoptosis test after treatment with fluorescent dyes. Blue dye stained viable cells while red elements corresponded to necrotic cells (scale bar, 100 μm); apoptotic cells were colored in green (scale bar, 50 μm). The images are representative of cells at 8th, 14th, and 20th generations. (D) Metabolic activity (MTT assay) of OA-IFP cells from 24 h to 14 days in culture. For the panels (B,D), results are the average of 3 technical replicates each referring to 9 patients.
FIGURE 3Ultrastructural characterization of OA-IFP stem cells. Toluidine Blue staining images (A) and TEM micrographs (B–E) of OA-IFP cells at P8 in culture. Black arrows in (C) and (D) show electron dense lysosomes and empty vesicles. Black asterisk in (E) shows secretion material resembling collagen fibrils outside the cytoplasm. M, mitochondria; N, nucleus; G, golgi apparatus; RER, rough endoplasmic reticulum. Scale bars, (A) 20 μm; (B) and (C) 2 μm; (D) and (E) 1 μm. (F) mRNA expression levels of CD38 and CALR in OA-IFP stem cells compared to human leukocytes (∗P < 0.5; ∗∗P < 0.01). For panel (F), results are the average of 3 technical replicates referring to 9 patients.
FIGURE 4Analysis of OA-IFP by qPCR, FCM and immunohistochemistry. OA-IFP subcultures from 8th generation and under proliferative conditions were analyzed at a sub-confluence state for stemness (A,B) or cellular responsivity markers (C,D) by qPCR (A) and FCM [FacsDiva and FlowJo software (B,D)] (B–D) where the histograms show the mean percentage of positive cells; samples treated with only secondary antibodies or isotype control antibodies were used as references. Three technical replicates for each sample were analyzed. (E) Double immunohistochemical analysis of OA-IFP tissue samples showing cellular elements positive to HLA-DR (red) and negative to CD45 (brown). Lymphocytic elements, positive to only CD45 (brown), were considered as an internal control of the method (black arrow, E,a) (Scale bar: 25 μm). FCM, flow cytometry analysis.
FIGURE 5OA-IFP stem cells responsiveness to environmental stimuli. (A) qPCR analysis of mRNA expression levels of COL1A1, SPARC, GLUT1, and CTTN gene on OA-IFP stem cells at a sub-confluence state; null-expression of GLUT4, CTTN, COL2A1, COL9A3, COL10A1 mRNAs was detected. (B) Response of OA-IFP stem cells to adipogenic stimuli. After 7 and 14 days from stimulation, the cells showed cytoplasmic red-stained lipid droplets; scale bars, 100 μm. (C) Response of OA-IFP stem cells to soluble (endothelial medium enriched of angiogenic factors) and mechanical stimuli (stiff and soft support) at 3 and 7 days from stimulation. OA-IFP stem cells seeded on plastic surface and cultured in proliferation medium represented the control-group; scale bars, 100 μm. (D) Image processing steps of images referring to OA-IFP stem cells cultured on stiff support, at 3 and 7 days from stimulation. After edge detection and threshold binary tools (a,e) the skeletons were calculated (b,f), before the analysis of branches (i.e., number and length) (c,g) and branching points (d,h). The processed images highlight the formation of the cord-like structures. For panel (A), results are the average of 3 technical replicates for each sample referring to 9 patients.